Ethereum Enters NASDAQ Treasury: BioNexus Leads the Charge

BioNexus Gene Lab Corp. (BGLC), a NASDAQ-listed healthcare tech firm based in Kuala Lumpur, announced on March 5 that it has adopted Ethereum (ETH) as its primary treasury asset—the first on the exchange to do so. 

The move by BioNexus represents the growing acceptance and role of blockchain technology in corporate finance, which can potentially set a trend for other public companies.

Strategy Rooted In ETH’s Strengths

BGLC’s action is driven by ETH’s liquidity, utility, and stability, as outlined in their Ethereum Strategy Whitepaper. 

The whitepaper refers to ETH’s institutional credibility and support by industry leaders like BlackRock and Fidelity as well as its ability to generate yields from staking with 3-5% annual returns. It also mentions the blockchain’s application in stablecoin transactions, supporting trillions of dollars in global finance, and its scalability, all of which will be improved by upcoming upgrades like Pectra.

Also read: Ethereum Sentiment Hits Yearly Low—A Rebound May Be Imminent

CEO Sam Tan claimed the strategy will strengthen BGLC’s finances and attract innovative investors. The firm plans to explore Wyoming’s stablecoin framework, using the state’s blockchain-friendly laws. 

With a $5.88 million market cap, $9.26 million in annual revenue, and a current ratio of 4.98, BGLC has the finance to support the new Strategy Crypto Reserve.

Why Ethereum?

The whitepaper breaks it down:  

• Institutional Trust: As of March 7, 2025, ETH’s market cap stands at $263 billion and it trades at approximately $2,188, with support from Grayscale and ETF approvals.  
• Yield Generation: Staking offers 3-5% returns, unlike cash or bonds.  
• Financial Role: The stablecoin market is worth $215 billion, which  is proof of Ethereum’s strength in DeFi and transactions.  
• Scalability: Pectra and Layer-2 improvements promise efficiency.

Together, these factors make ETH a forward-thinking, flexible choice for treasury management, matching Bionexus’s innovative approach in healthcare.

BGLC expects to capitalize on staking yields and institutional support, eyeing Ethereum-based tools and Wyoming’s stablecoin system as the first Nasdaq-listed firm to adopt Ethereum Treasury.

Also read: Ethereum’s Pectra Upgrade is Here – Will It Revolutionize Staking and ETFs?

Ethereum’s rising use in corporate institutions—through tokenized assets, decentralized payments, and DeFi—supports BGLC’s decision.

In biotech, this could redefine liquidity strategies and how it is managed, though success depends on clear regulatory and market acceptance.